{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T12:47:52Z","timestamp":1773060472809,"version":"3.50.1"},"reference-count":23,"publisher":"American Association of Psychiatric Pharmacists (AAPP)","issue":"5","license":[{"start":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T00:00:00Z","timestamp":1696204800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Neuropsychiatric symptoms associated with long COVID are a growing concern. A proposed pathophysiology is increased inflammatory mediators. There is evidence that typical serotonergic antidepressants have limited efficacy in the presence of inflammation. Although ketamine has shown promise in MDD, there is limited evidence supporting the use of ketamine to treat depressive symptoms associated with long COVID.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Case Report<\/jats:title>\n                  <jats:p>This case took place on an inpatient psychiatry unit in a Canadian hospital. The patient was admitted with a 10-month history of worsening depression and suicidality following infection with COVID-19. Depressive symptoms and suicidal ideation were assessed throughout treatment using the Montgomery-Asberg Depression Rating Scale (MADRS). Written informed consent was obtained prior to data collection. This patient received 4 doses of intranasal ketamine which resulted in rapid improvement of depressive symptoms and complete resolution of suicidality with no major adverse events.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Discussion<\/jats:title>\n                  <jats:p>There is evidence to support long COVID symptoms result from dysregulated inflammatory processes. The presence of inflammation in patients with MDD has correlated to poor outcomes with first-line antidepressants. It has been demonstrated that IV ketamine is associated with decreased inflammatory mediators and proportional decrease in depressive symptoms.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Intranasal ketamine in this case was effective at treating depressive symptoms and suicidal ideation associated with long COVID. This is consistent with available data that demonstrates ketamine's efficacy in reducing inflammatory mediators associated with neuropsychiatric symptoms. Therefore, ketamine may be a potential therapeutic option to treat long COVID and persistent depressive symptoms.<\/jats:p>\n               <\/jats:sec>","DOI":"10.9740\/mhc.2023.10.239","type":"journal-article","created":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T00:01:48Z","timestamp":1696204908000},"page":"239-243","source":"Crossref","is-referenced-by-count":4,"title":["Intranasal ketamine as a treatment for psychiatric complications of long COVID: A case report"],"prefix":"10.9740","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5439-9123","authenticated-orcid":true,"given":"Kaitlyn","family":"Baldwin","sequence":"first","affiliation":[{"name":"1 Pharmacy Resident, University of British Columbia, Lower Mainland Pharmacy Services, Vancouver, British Columbia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8920-5819","authenticated-orcid":true,"given":"Annabelle","family":"Wanson","sequence":"additional","affiliation":[{"name":"2 Psychiatrist and Area Department Lead (Interim), Saskatchewan Health Authority, Saskatoon, Saskatchewan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6086-6752","authenticated-orcid":true,"given":"Lee-Anne","family":"Gilecki","sequence":"additional","affiliation":[{"name":"3 Psychiatrist, Saskatchewan Health Authority, Saskatoon, Saskatchewan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0222-3956","authenticated-orcid":true,"given":"Courtney","family":"Dalton","sequence":"additional","affiliation":[{"name":"3 Psychiatrist, Saskatchewan Health Authority, Saskatoon, Saskatchewan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7272-4484","authenticated-orcid":true,"given":"Evyn","family":"Peters","sequence":"additional","affiliation":[{"name":"5 Psychiatrist, Saskatchewan Health Authority, Saskatoon, Saskatchewan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6141-0439","authenticated-orcid":true,"given":"Katelyn","family":"Halpape","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4719","published-online":{"date-parts":[[2023,10,2]]},"reference":[{"issue":"(11)","key":"2023100200014173800_i2168-9709-13-5-239-b01","doi-asserted-by":"crossref","first-page":"340","DOI":"10.24095\/hpcdp.41.11.04","article-title":"Symptoms of major depressive disorder during the COVID-19 pandemic: results from a representative sample of the Canadian population","volume":"41","author":"Shields","year":"2021","journal-title":"Health Promot Chronic Dis Prev Can"},{"issue":"(1)","key":"2023100200014173800_i2168-9709-13-5-239-b02","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1176\/appi.ajp.163.1.28","article-title":"Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice","volume":"163","author":"Trivedi","year":"2006","journal-title":"Am J Psychiatry"},{"issue":"(10)","key":"2023100200014173800_i2168-9709-13-5-239-b03","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/pcn.12902","article-title":"Rapid-acting antidepressant ketamine, its metabolites and other candidates: a historical overview and future perspective","volume":"73","author":"Hashimoto","year":"2019","journal-title":"Psychiatry Clin Neurosci"},{"issue":"(2)","key":"2023100200014173800_i2168-9709-13-5-239-b04","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/0706743720970860","article-title":"The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force recommendations for the use of racemic ketamine in adults with major depressive disorder: recommandations du roupe De Travail Du R\u00e9seau Canadien Pour Les Traitements De L'humeur Et De L'anxi\u00e9t\u00e9 (Canmat) concernant l'utilisation de la k\u00e9tamine rac\u00e9mique chez les adultes souffrant de trouble d\u00e9pressif majeur","volume":"66","author":"Swainson","year":"2021","journal-title":"Can J Psychiatry"},{"issue":"(3)","key":"2023100200014173800_i2168-9709-13-5-239-b05","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jad.2019.11.086","article-title":"Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: a randomized, double-blind, non-inferiority study","volume":"264","author":"Correia-Melo","year":"2020","journal-title":"J Affect Disord"},{"issue":"(9)","key":"2023100200014173800_i2168-9709-13-5-239-b06","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s40262-016-0383-6","article-title":"Ketamine: a review of clinical pharmacokinetics and pharmacodynamics in anesthesia and pain therapy","volume":"55","author":"Peltoniemi","year":"2016","journal-title":"Clin Pharmacokinet"},{"issue":"(7)","key":"2023100200014173800_i2168-9709-13-5-239-b07","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1176\/appi.ajp.2018.17060720","article-title":"Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study","volume":"175","author":"Canuso","year":"2018","journal-title":"Am J Psychiatry"},{"issue":"(2)","key":"2023100200014173800_i2168-9709-13-5-239-b08","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1001\/jamapsychiatry.2017.3739","article-title":"Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial","volume":"75","author":"Daly","year":"2018","journal-title":"JAMA Psychiatry"},{"key":"2023100200014173800_i2168-9709-13-5-239-b09","article-title":"Esketamine for treatment-resistant depression. 2019 Apr 1","author":"Tibensky","journal-title":"CADTH issues in emerging health technologies. Canadian Agency for Drugs and Technologies in Health; 2016"},{"issue":"(12)","key":"2023100200014173800_i2168-9709-13-5-239-b10","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.biopsych.2014.03.026","article-title":"A randomized controlled trial of intranasal ketamine in major depressive disorder","volume":"76","author":"Lapidus","year":"2014","journal-title":"Biol Psychiatry"},{"issue":"(4)","key":"2023100200014173800_i2168-9709-13-5-239-b11","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/s41591-021-01283-z","article-title":"Post-acute COVID-19 syndrome","volume":"27","author":"Nalbandian","year":"2021","journal-title":"Nat Med"},{"issue":"(10270)","key":"2023100200014173800_i2168-9709-13-5-239-b12","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S0140-6736(20)32656-8","article-title":"RETRACTED: 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study","volume":"397","author":"Huang","year":"2021","journal-title":"Lancet"},{"issue":"(47)","key":"2023100200014173800_i2168-9709-13-5-239-b13","doi-asserted-by":"crossref","first-page":"e409","DOI":"10.3346\/jkms.2020.35.e409","article-title":"Psychological consequences of survivors of COVID-19 pneumonia 1 month after discharge","volume":"35","author":"Park","year":"2020","journal-title":"J Korean Med Sci"},{"issue":"(5)","key":"2023100200014173800_i2168-9709-13-5-239-b14","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S2215-0366(21)00084-5","article-title":"6-month neurological and psychiatric outcomes in 236\u2009379 survivors of COVID-19: a retrospective cohort study using electronic health records","volume":"8","author":"Taquet","year":"2021","journal-title":"Lancet Psychiatry"},{"issue":"(17)","key":"2023100200014173800_i2168-9709-13-5-239-b15","first-page":"71","article-title":"Spectrum of neuropsychiatric manifestations in COVID-19","volume":"88","author":"Nalleballe","year":"2020","journal-title":"Reddy"},{"issue":"(10)","key":"2023100200014173800_i2168-9709-13-5-239-b16","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S2215-0366(20)30287-X","article-title":"Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study","volume":"7","author":"Varatharaj","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"2023100200014173800_i2168-9709-13-5-239-b17","doi-asserted-by":"crossref","first-page":"105295","DOI":"10.1016\/j.psyneuen.2021.105295","article-title":"Interleukin-6 as potential mediator of long-term neuropsychiatric symptoms of COVID-19","volume":"131","author":"Kappelmann","year":"2021","journal-title":"Psychoneuroendocrinology"},{"issue":"(1)","key":"2023100200014173800_i2168-9709-13-5-239-b18","doi-asserted-by":"crossref","first-page":"iqab004","DOI":"10.1093\/oxfimm\/iqab004","article-title":"What can neuroimmunology teach us about the symptoms of long-COVID?","volume":"2","author":"Mondelli","year":"2021","journal-title":"Oxf Open Immunol"},{"key":"2023100200014173800_i2168-9709-13-5-239-b19","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.bbi.2021.02.021","article-title":"Persistent psychopathology and neurocognitive impairment in COVID-19 survivors: effect of inflammatory biomarkers at three-month follow-up","volume":"94","author":"Mazza","year":"2021","journal-title":"Brain Behav Immun"},{"key":"2023100200014173800_i2168-9709-13-5-239-b20","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3389\/fpsyt.2019.00458","article-title":"Low-grade inflammation as a predictor of antidepressant and anti-inflammatory therapy response in MDD patients: a systematic review of the literature in combination with an analysis of experimental data collected in the EU-MOODINFLAME consortium","volume":"10","author":"Arteaga-Henr\u00edquez","year":"2019","journal-title":"Front Psychiatry"},{"issue":"(1)","key":"2023100200014173800_i2168-9709-13-5-239-b21","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/s41398-020-00933-z","article-title":"Alterations of multiple peripheral inflammatory cytokine levels after repeated ketamine infusions in major depressive disorder","volume":"10","author":"Zhan","year":"2020","journal-title":"Transl Psychiatry"},{"issue":"(1)","key":"2023100200014173800_i2168-9709-13-5-239-b22","doi-asserted-by":"crossref","first-page":"100100","DOI":"10.1016\/j.psycr.2022.100100","article-title":"Successful use of ketamine to treat severe depression with suicidality post-COVID-19 \u2013 a case report","volume":"2","author":"Meha","year":"2023","journal-title":"Psychiatry Res Case Reports"},{"key":"2023100200014173800_i2168-9709-13-5-239-b23","article-title":"FDA alerts health care professionals of potential risks associated with compounded ketamine nasal spray","volume-title":"FDA [Internet]"}],"container-title":["Mental Health Clinician"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/meridian.allenpress.com\/mhc\/article-pdf\/13\/5\/239\/3271039\/i2168-9709-13-5-239.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/meridian.allenpress.com\/mhc\/article-pdf\/13\/5\/239\/3271039\/i2168-9709-13-5-239.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T16:23:29Z","timestamp":1731687809000},"score":1,"resource":{"primary":{"URL":"https:\/\/mhc.kglmeridian.com\/view\/journals\/mhcl\/13\/5\/article-p239.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,1]]},"references-count":23,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,10,2]]},"published-print":{"date-parts":[[2023,10,1]]}},"URL":"https:\/\/doi.org\/10.9740\/mhc.2023.10.239","relation":{},"ISSN":["2168-9709"],"issn-type":[{"value":"2168-9709","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,1]]}}}